Raily Aesthetic Medicine International Holdings Limited (HKG:2135)
0.1220
-0.0080 (-6.15%)
Sep 19, 2025, 11:07 AM HKT
HKG:2135 Revenue
Raily Aesthetic Medicine International Holdings had revenue of 84.60M CNY in the half year ending June 30, 2025, a decrease of -13.30%. This brings the company's revenue in the last twelve months to 166.47M, down -20.46% year-over-year. In the year 2024, Raily Aesthetic Medicine International Holdings had annual revenue of 199.34M with 5.26% growth.
Revenue (ttm)
166.47M CNY
Revenue Growth
-20.46%
P/S Ratio
0.40
Revenue / Employee
574.02K CNY
Employees
290
Market Cap
72.42M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 199.34M | 9.96M | 5.26% |
Dec 31, 2023 | 189.38M | 24.86M | 15.11% |
Dec 31, 2022 | 164.52M | -23.85M | -12.66% |
Dec 31, 2021 | 188.37M | 23.82M | 14.48% |
Dec 31, 2020 | 164.55M | -26.61M | -13.92% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
JD Health International | 71.34B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
WuXi Biologics | 21.98B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |